Inventories of generic semaglutide are building up across India's pharmaceutical trade channels, with several brands holding over 50 days of stock in May.

India

Who

Dr. Reddy's, Glenmark, Mankind, Abbott, Zydus Lifesciences, Dr. Anoop Misra, Rajesh Pherwani, Dr Nandita Palshetkar, Sheetal Sapale, J.S. Shinde, Rajiv Singhal

What

When

Fri, 12 Jun 2026 14:41:19 GMT · 1h 47m ago

Where

India ·

Why

Despite a large potential market, actual drug adoption for obesity treatments in India is lower than anticipated due to clinical eligibility constraints, affordability issues, patient reluctance, and selective prescribing habits.

The Frontline Impact

How this affects you

The lower-than-expected adoption of generic semaglutide for obesity in India highlights a disconnect between disease prevalence and actual drug use, indicating significant market friction in a country with a large obese population.

Story chain

1 event in this thread

No related history yet - this is the origin event.

Verified Sources & Citations

Business Today
https://www.businesstoday.in/india/story/waistlines-expand-but-drug-stocks-pile-up-is-indias-weight-loss-boom-fading-536655-2026-06-12
HIGH

Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.